Every material Form 8-K ABVC BIOPHARMA, INC. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 30, 2026, ABVC BioPharma sold senior convertible notes with $4,106,060 in principal for a purchase price of $3,387,500, maturing June 30, 2027. The company also agreed on October 26 to pay Lind $625,000 to settle a New York lawsuit and retire its earlier Lind notes, while Lind's warrant rises by 20%. Because the notes convert into common stock at a discount, shareholders may face dilution.
Notes: $4,106,060 principal, $3,387,500 purchase price, 17.5% original issue discount, maturity June 30, 2027
Conversion at 85% of the average of three VWAPs, with a $0.2 floor price; issuance capped at 19.99% of shares outstanding unless shareholders approve by June 30, 2027
ABVC BioPharma completed the separation of its subsidiary BioKey Cayman, distributing about 15% of BioKey Cayman's ordinary shares to ABVC common stockholders as a pro rata dividend effective August 21, 2026. ABVC retains about 85% ownership and control, and BioKey Cayman is no longer a wholly owned subsidiary, but no trading market for its shares exists yet and it intends to seek OTC Markets quotation.
Distribution of 4,500,390 BioKey Cayman ordinary shares, at 0.169464 share per ABVC common share held at the close of business on July 24, 2026
Distribution effective 11:59 p.m. New York City time on August 21, 2026; ABVC holds approximately 85% of BioKey Cayman
No trading market exists yet; BioKey Cayman plans to seek OTC Markets quotation and has no trading symbol
ABVC BioPharma said on August 3, 2026 that it has postponed the previously announced distribution of BioKey (Cayman), Inc. ordinary shares, which had been scheduled for the same day. The company needs more time to complete administrative, regulatory and tax-related matters, and it is coordinating with Nasdaq, DTC and its transfer agent on revised mechanics and new dates.
Distribution scheduled for August 3, 2026 has been postponed; no new date has been set
Record date is unchanged and the distribution ratio remains 0.169464 BioKey ordinary shares per ABVC common share
The previously announced ex-dividend date no longer applies and will be revised; the company will announce the new dates once finalized
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ABVC BIOPHARMA, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →